|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant protein corresponding to full length Galectin-3|
|Storage buffer||tissue culture supernatant|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:80|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-12367 targets Galectin-3 in IHC (P) applications and shows reactivity with Human samples.
The MA5-12367 immunogen is recombinant protein corresponding to full length Galectin-3.
Galectin-3 is a homotypical cell adhesion lectin binding to beta-galactosidase and laminin. It is down regulated in certain colon cancers and breast cancers facilitating their metastasis. It has been proved to be a useful marker for anaplastic large cell lymphoma.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Immunohistochemical clue for the histological overlap of salivary adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma.
MA5-12367 was used in immunohistochemistry to study the potential of immunohistochemistry to distinguish alivary adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma
|El-Nagdy S,Salama NM,Mourad MI||Interventional medicine and applied science (5:131)||2013|
Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia.
MA5-12367 was used in immunohistochemistry to study the prognostic value of bone marrow LGALS3 expression in acute myeloid leukemia
|Cheng CL,Hou HA,Lee MC,Liu CY,Jhuang JY,Lai YJ,Lin CW,Chen HY,Liu FT,Chou WC,Chen CY,Tang JL,Yao M,Huang SY,Ko BS,Wu SJ,Tsay W,Tien HF||Blood (121:3172)||2013|
Investigation of galectin-3 and heparanase in endometrioid and serous carcinomas of the endometrium and correlation with known predictors of survival.
MA5-12367 was used in immunohistochemistry to investigate the effect of galectin-3 and heparanase on the pathogenesis of endometrial carcinomas
|Ege CB,Akbulut M,Zekio?lu O,Ozdemir N||Archives of gynecology and obstetrics (284:1231)||2011|
Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma.
MA5-12367 was used in immunohistochemistry to investigate the role of galectin 3 in the diagnosis and prognosis of cutaneous melanoma
|Abdou AG,Hammam MA,Farargy SE,Farag AG,El Shafey EN,Farouk S,Elnaidany NF||The American Journal of dermatopathology (32:809)||2010|
Immunohistochemical galectin-3 expression in non-melanoma skin cancers.
MA5-12367 was used in immunohistochemistry to investigate the distribution of galectin-3 in cutaneous squamous cell carcinoma basal cell carcinoma
|Kapucuoglu N,Basak PY,Bircan S,Sert S,Akkaya VB||Pathology, research and practice (205:97)||2009|
Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma.
MA5-12367 was used in immunohistochemistry to examine the role of galectin-3 in the tumorigenesis of papillary thyroid carcinoma
|T?rk?z HK,Oks?z H,Yurdakul Z,Ozcan D||Endocrine pathology (19:92)||2008|
Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling.
MA5-12367 was used in immunohistochemistry to identify the diagnostic markers for papillary thyroid carcinoma
|Murphy KM,Chen F,Clark DP||Human pathology (39:420)||2008|
Galectin-3 expression is a potent prognostic marker in colorectal cancer.
MA5-12367 was used in immunohistochemistry to investigate the prognostic significance of galectin-3 in colorectal cancer
|Endo K,Kohnoe S,Tsujita E,Watanabe A,Nakashima H,Baba H,Maehara Y||Anticancer research (25:3117)||2005|
T cell apoptosis at the maternal-fetal interface in early human pregnancy, involvement of galectin-1.
MA5-12367 was used in western blot to investigate the effect of galectin-1 on the development of an immune-privileged environment at the maternal-fetal junction
|Kopcow HD,Rosetti F,Leung Y,Allan DS,Kutok JL,Strominger JL||Proceedings of the National Academy of Sciences of the United States of America (105:18472)||2008|